A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

Trial Profile

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Zastumotide (Primary) ; AS15
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DERMA; MAGE3-AS15-MEL-005
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Aug 2016 This trial was completed in Belgium, according to European Clinical Trials Database.
    • 16 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top